Report Detail

Request for Sample of this report

Global Personalized Medicine Partnering 2010-2017: Deal trends, players, financials and forecasts

Published: November 2017

No. of Pages: 1000

Price:

Single User License: US $ 3495

Corporate User License: US $ 17495

Report Description
Table of Contents

"Delivery of this report will take 1-3 days after purchase."

The Global Personalized Medicine Partnering 2010-2017 report provides comprehensive understanding and unprecedented access to the personalized medicine partnering deals and agreements entered into by the worlds leading healthcare companies.

This report provides details of the latest Personalized Medicine agreements announced in the life sciences since 2010.

The report takes the reader through a comprehensive review Personalized Medicine deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Personalized Medicine partnering deals.

The report presents financial deal term values for Personalized Medicine deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Personalized Medicine partnering field; both the leading deal values and most active Personalized Medicine dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 1,370 online deal records of actual Personalized Medicine deals, as disclosed by the deal parties, are included towards the end of the report in a directory format by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of Personalized Medicine dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Personalized Medicine dealmaking since 2010, including details of headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Personalized Medicine deals since 2010. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Personalized Medicine dealmaking with a brief summary followed by a comprehensive listing of Personalized Medicine deals announded by that company, as well as contract documents, where available.

Chapter 5 provides a comprehensive and detailed review of Personalized Medicine partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of Personalized Medicine partnering deals signed and announced since Jan 2010. The chapter is organized by specific Personalized Medicine technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

A comprehensive series of appendices is provided organized by Personalized Medicine partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Personalized Medicine partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Personalized Medicine technologies and products.

Key benefits

Global Personalized Medicine Partnering 2010-2017: Deal trends, players, financials and forecasts provides the reader with the following key benefits:

In-depth understanding of Personalized Medicine deal trends since 2010
Access to headline, upfront, milestone and royalty data
Analysis of the structure of Personalized Medicine agreements with numerous real life case studies
Detailed access to actual Personalized Medicine contracts entered into by leading biopharma companies
Identify most active Personalized Medicine dealmakers since 2010
Insight into terms included in a Personalized Medicine partnering agreement, with real world examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

Global Personalized Medicine Partnering 2010-2017: Deal trends, players, financials and forecasts is intended to provide the reader with an in-depth understanding and access to Personalized Medicine trends and structure of deals entered into by leading companies worldwide.

Personalized Medicine Partnering Terms and Agreements includes:

Trends in Personalized Medicine dealmaking in the biopharma industry since 2010
Analysis of Personalized Medicine deal structure
Access to headline, upfront, milestone and royalty data
Case studies of real-life Personalized Medicine deals
Access to Personalized Medicine contract documents
Leading Personalized Medicine deals by value since 2010
Most active Personalized Medicine dealmakers since 2010

In Global Personalized Medicine Partnering 2010-2017: Deal trends, players, financials and forecasts, the available deals are listed by:

Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific therapy target
Technology type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Personalized Medicine Partnering 2010-2017: Deal trends, players, financials and forecasts report provides comprehensive access to available deals and contract documents for over 1,370 Personalized Medicine deals.

Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How aresalesand payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 Introduction

Chapter 2 Trends in Personalized Medicine dealmaking
2.1. Introduction
2.2. Personalized Medicine partnering over the years
2.3. Most active Personalized Medicine dealmakers
2.4. Personalized Medicine partnering by deal type
2.5. Personalized Medicine partnering by therapy area
2.6. Deal terms for Personalized Medicine partnering
2.6.1 Personalized Medicine partnering headline values
2.6.2 Personalized Medicine deal upfront payments7
2.6.3 Personalized Medicine deal milestone payments
2.6.4 Personalized Medicine royalty rates

Chapter 3 Leading Personalized Medicine deals
3.1. Introduction
3.2. Top Personalized Medicine deals by value

Chapter 4 Most active Personalized Medicine dealmakers
4.1. Introduction
4.2. Most active Personalized Medicine dealmakers
4.3. Most active Personalized Medicine partnering company profiles

Chapter 5 Personalized Medicine contracts dealmaking directory
5.1. Introduction
5.2. Personalized Medicine contracts dealmaking directory

Chapter 6 Personalized Medicine dealmaking by technology type

Chapter 7 Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

Appendices

Appendix 1 Personalized Medicine deals by company A-Z

Appendix 2 Personalized Medicine deals by stage of development

Discovery
Preclinical
Phase I
Phase II
Phase III
Regulatory
Marketed
Formulation

Appendix 3 Personalized Medicine deals by deal type

Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Litigation
Manufacturing
Marketing
Material transfer
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Technology transfer
Termination
Warranty

Appendix 4 Personalized Medicine deals by therapy area

Appendix 5 Deal type definitions

About Wildwood Ventures

Current Partnering
Current Agreements
Recent report titles from Current Partnering

List of Figures

Figure 1: Personalized Medicine partnering since 2010
Figure 2: Active Personalized Medicine dealmaking activity since 2010
Figure 3: Personalized Medicine partnering by deal type since 2010
Figure 4: Personalized Medicine partnering by disease type since 2010
Figure 5: Personalized Medicine deals with a headline value
Figure 6: Personalized Medicine deals with an upfront value
Figure 7: Personalized Medicine deals with a milestone value
Figure 8: Personalized Medicine deals with a royalty rate value
Figure 9: Top Personalized Medicine deals by value since 2010
Figure 10: Most active Personalized Medicine dealmakers since 2010
Figure 11: Online partnering resources
Figure 12: Forthcoming partnering events

Published By: Current Partnering

Product Code: Current Partnering538

Related Reports

Did you find what you are/were looking for ? If not, read below and browse through other relevant pages for similar market research reports OR get in touch with us through the form/contact info in your right navigation panel and well share relevant market report titles for you to explore.

Global Neutropenia Treatment Market Size, Status and Forecast 2019-2025 Neutropenia is an abnormal condition, characterized by critically low levels of circulating neutrophils, a type of WBC found in the blood. These cells make up for the majority of circulating lymphocytes and help defend the body against infections by bacteria, viruses, and other pathogenic organisms....
Global Myelodysplastic Syndrome Market Insights, Forecast to 2025 Myelodysplastic syndromes (MDS) are a group of cancers in which immature blood cells in the bone marrow do not mature and therefore do not become healthy blood cells.[2] Early on there are typically no symptoms.Later symptoms may include feeling tired, shortness of breath, easy bleeding, or frequent...
Global Myasthenia Gravis Drugs Market Insights, Forecast to 2025 Acetylcholine esterase (AChE) inhibitors are considered to be the basic treatment of myasthenia gravis (MG). Edrophonium is primarily used as a diagnostic tool owing to its short half-life. Pyridostigmine is used for long-term maintenance. The market is witnessing the rapid development of nov...
Global Musculoskeletal Disorders Therapeutics Market Size, Status and Forecast 2019-2025 Musculoskeletal disorders are the group of pain disorders or injuries that affect the body's joints, muscles, nerves, ligaments, tendons, and structures, all of which support the hands, legs, neck and back. The pain and discomfort vary with the severity of the condition. These disorders have a wide ...
Global Muscle Relaxant Drugs Market Insights, Forecast to 2025 Muscle spasticity is caused by damage to the spinal cord or brain. Nerves in the brain and spinal cord help relax the muscles during the idle state. Conditions that affect the brain or spinal cord such as multiple sclerosis, cerebral palsy, and stroke can interfere with normal muscle relaxation, lea...
Global Multiple Sclerosis Market Size, Status and Forecast 2019-2025 Multiple sclerosis is a chronic, inflammatory medical condition, which results in demyelination, axonal transection, and neurodegeneration of the nerve cells of the brain and spinal cord. The immune system of the body targets the neurons within the CNS and damages the myelin sheath. It is a potentia...
Global MRSA Drugs Market Insights, Forecast to 2025 Staphylococcus aureus is a bacteria commonly found on nose or skin of healthy people. MRSA i.e., methicillin-resistant staphylococcus aureus, is thus a type of staphylococcus aureus that is resistant to beta-lactam antibiotic called methicillin. MRSA strains do not respond to methicillin treatment. ...
Global Mouth Ulcer Market Size, Status and Forecast 2019-2025 Mouth ulcers are common and should clear up on their own within a week or two. They're rarely a sign of anything serious but may be uncomfortable to live with. The morden life, people work for extra hours to meet the deliverables at their jobs. This change in lifestyle has resulted in people ...
Global Gastrointestinal OTC Drugs Market Size, Status and Forecast 2019-2025 Gastrointestinal OTC drugs are used for indications such as GERD, vomiting, constipation, diarrhea, and flatulence. Some of the OTC drugs that are available for the treatment of gastrointestinal diseases are laxatives, anti-flatulents, H2-antaginists, anti-diarrheals, PPIs, and anti-emetics. The OTC...
Global Foot and Mouth Disease Vaccines Market Insights, Forecast to 2025 Foot and Mouth Disease (FMD) vaccines are vaccines that provide active acquired immunity to Foot and Mouth Disease (FMD). Foot and Mouth Disease (FMD) is a highly contagious viral disease that primarily affects cloven-hooved livestock and wildlife like cattle, pigs, sheep and goats. China is ...

We are on:

Why ReportsnReports.com?

500,000 market research reports and growing.
Top Fortune 500 Organizations trust us for research data.
24/7 support on call as well as emails.
Your Details are safe with us.
Free support for your research requirements.
Report Delivery: Email
Delivery Time:
- Upto 24 hrs - working days
- Upto 48 hrs max - weekends and public holidays

Need Help?

Name *

Email *

Phone *

Country *

Subject *

Comments *